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Abstract
Introduction:  Several  approaches  have  been  tried  for  the  treatment  of  tinnitus,  from  cognitive-
behavioral  therapies  and  sound  enrichment  to  medication.  In  this  context,  antioxidants,  widely
used in  numerous  areas  of  medicine,  appear  to  represent  a  promising  approach  for  the  control
of this  symptom,  which  often  is  poorly  controlled.
Objective:  To  evaluate  the  effects  of  antioxidant  therapy  for  tinnitus  in  a  group  of  elderly
patients.
Methods: Prospective,  randomized,  double-blinded,  placebo-controlled  clinical  trial.  The  sam-
ple consisted  of  58  subjects  aged  60  years  or  older,  with  a  complaint  of  tinnitus  associated  with
sensorineural  hearing  loss.  These  individuals  completed  the  Tinnitus  Handicap  Inventory  (THI)
questionnaire  before  and  after  six  months  of  therapy.  The  treatment  regimens  were:  Ginkgo
biloba dry  extract  (120  mg/day),  -lipoic  acid  (60  mg/day)  +  vitamin  C  (600  mg/day),  papaverine
hydrochloride  (100  mg/day)  +  vitamin  E  (400  mg/day),  and  placebo.
Results:  There  was  no  statistically  signiﬁcant  difference  between  THI  by  degree  (p  =  0.441)  and
by score  (p  =  0.848)  before  and  after  treatment.
Conclusion:  There  was  no  beneﬁt  from  the  use  of  antioxidant  agents  for  tinnitus  in  this  sample.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Published  by
Elsevier Editora  Ltda.  All  rights  reserved.
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Efeito  da  terapia  com  antioxidantes  sobre  o  zumbido  em  idosos
Resumo
Introduc¸ão:  Uma  série  de  abordagens  terapêuticas  tem  sido  empregada  no  tratamento  do
zumbido, desde  terapias  cognitivo-comportamentais  e  de  enriquecimento  sonoro  até  terapias
medicamentosas.  Nesse  contexto,  os  agentes  antioxidantes,  amplamente  utilizados  em  diver-
sas áreas  da  medicina,  parecem  representar  uma  perspectiva  promissora  para  o  controle  desse
sintoma,  que  muitas  vezes  tem  um  controle  clínico  insatisfatório.
Objetivo:  Avaliar  os  efeitos  da  terapia  com  agentes  antioxidantes  sobre  o  zumbido  em  um  grupo
de pacientes  idosos.
Método:  Ensaio  clínico  prospectivo,  randomizado,  duplo-cego  e  controlado  por  placebo.A
amostra composta  de  58  indivíduos  com  60  anos  ou  mais,  com  queixa  clínica  de  zumbido  asso-
ciado à  perda  auditiva,  do  tipo  neurossensorial,  em  graus  variados.  Esses  indivíduos  foram
submetidos  ao  questionário  THI  (Tinnitus  Handicap  Inventory)  antes  e  após  6  meses  de  uso
da medicac¸ão.  Os  esquemas  terapêuticos  foram  os  seguintes:  extrato  seco  de  Ginkgobiloba
(120 mg/dia),  ácido  -lipóico  (60  mg/dia)  +  vitamina  C  (600  mg/dia),  cloridrato  de  papaverina
(100 mg/dia)  +  vitamina  E  (400  mg/dia)  e  placebo.
Resultados:  O  THI  após  o  tratamento  foi  estatisticamente  igual  ao  THI  antes  do  tratamento,
tanto em  graus  (p  =  0,441)  quanto  em  escores  (p  =  0,848).
Conclusão:  Não  se  veriﬁcou  benefício  estatisticamente  signiﬁcativo  com  o  uso  de  agentes
antioxidantes  para  o  zumbido  dos  indivíduos  avaliados.
© 2015  Associac¸a˜o  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Ce´rvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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with  clinical  contraindications  to  the  use  of  these  substancesntroduction
innitus,  whose  prevalence  is  estimated  at  approximately
0%  of  the  adult  population,  has  repercussions  and  an  impact
n  quality  of  life  of  the  affected  individuals,  that  varies
rom  a  slight  perception  without  discomfort  to  an  extreme
ompromise  in  quality  of  life.1
For  those  whose  tinnitus  has  signiﬁcant  clinical  impact,
 number  of  therapeutic  approaches  have  been  described
nd  employed,  from  cognitive-behavioral  therapies  and
ound  enrichment,  to  drug  approaches.  Some  studies  have
hown  favorable  results,  while  others  did  not  result  in
eneﬁts.2 Various  substances  have  been  used  and  tested  as
rug  treatments.  Among  them,  antioxidants  have  appeared
romising.2 Antioxidants  encompass  a  wide  range  of  sub-
tances  whose  primary  function  is  the  neutralization  and
learance  of  free  radicals,  that  is,  because  of  their
olecular  conﬁguration,  result  in  being  toxic  and  harm-
ul  to  cells  and  tissues.  With  respect  to  the  auditory
ystem,  the  action  of  free  radicals  in  cochlear  physi-
logy  has  been  demonstrated  experimentally.3--6 In  the
ase  of  auditory  disorders,  antioxidants  have  been  used
n  sudden  deafness,  to  try  to  prevent  ototoxicity,  and
or  acute  acoustic  trauma,7,8 as  well  as  in  the  approach
o  presbycusis,  sometimes  with  conﬂicting  results.9,10 In
ases  of  tinnitus,  probably  the  substance  most  widely
sed  and  studied  currently  is  Ginkgo  biloba, an  herbal
ntioxidant.  Associations  of  antioxidants,  vitamins,  and
hospholipids  administered  to  patients  diagnosed  with  idio-
athic  tinnitus  demonstrated  relief  of  this  condition  and
ecreased  serum  levels  of  free  radicals  in  a  case  series
tudy.11
w
u
sThus,  it  was  decided  to  test  the  effects  of  antioxidants  on
innitus  in  a  group  of  elderly  patients  in  a  controlled  clinical
tudy.
ethods
he  research  project  was  submitted  to  the  Ethics  Commit-
ee  on  Institutional  Research  and  approved  under  No.  CEP
723/10.
The  research  was  registered  with  the  International
linical  Trials  platform  of  the  World  Health  Organization  at:
ttp://apps.who.int/trialsearch/trial.aspx?trialid=ACTRN
2610000667011.
The  sample  was  composed  of  58  male  and  female  sub-
ects  aged  60  years  or  older  with  clinical  complaints  of
innitus  associated  with  a  variable  degree  of  sensorineu-
al  hearing  loss  conﬁrmed  by  previous  audiometric  testing.
hese  subjects  were  administered  the  Tinnitus  Handicap
nventory  (THI)  questionnaire12 before  and  after  medica-
ion  use.  THI  is  a  scale  that  measures  discomfort  caused
y  tinnitus,  with  questions  related  to  everyday  annoyances
nd  losses  attributed  to  the  symptom,  deﬁning  a  different
umeric  value  for  each  afﬁrmative  or  negative  answer,  or
or  partial  agreement.  The  ﬁnal  sum  (score)  is  framed  by  a
radation  (degree),  from  1  (slight,  only  perceived  in  quiet
nvironments)  to  5  (catastrophic).  In  the  sample  selection,
ubjects  with  known  allergy  to  any  substance  to  be  tested  orere  excluded.  Anticoagulant  users  or  subjects  with  coag-
lopathy,  as  well  as  diabetics,  were  also  excluded  from  the
ample.
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Table  1  Proﬁle  of  individuals  with  complaints  of  tinnitus.
Gender
Male  26  44.8%
Female 32  55.2%
Age (years)
Mean  72.6
Median  73.0
Minimum  60.0
Maximum  89.0
Standard  deviation  6.6
Education
Illiterate  1  1.7%
Literate  7  12.1%
Elementary  school  38  65.5%
High school  10  17.2%
College 2  3.4%
Professional  occupation
Retired  49  84.5%
Unemployed  1  1.7%
Employed  8  13.8%
Smoking
No 53  91.4%
Yes 5  8.6%
Alcohol  consumption
No  50  86.2%
Yes 8  13.8%
Number  of  medications
None  4  6.9%
1 17  29.3%
2 17  29.3%
3 8  13.8%
4 6  10.3%
5 3  5.2%
6 2  3.4%
Table  2  Distribution  of  the  presence  of  comorbidities
reported  by  patients  with  complaints  of  tinnitus.
Hearing  aid  use
No  55  94.8%
Yes 3  5.2%
Systemic  blood  hypertension
No  20  34.5%
Yes 38 65.5%
Dyslipidemia
No 49  84.5%
Yes 9 15.5%
Heart disease
No  58  100.0%
Yes --  --
Hypothyroidism
No 49  84.5%
Yes 9  15.5%
Osteoporosis
No 49  84.5%
Yes 9  15.5%
Arthropathy
No 52  89.7%
Yes 6  10.3%
Benign  prostatic  hyperplasia  (among  men)
No 22  84.6%
Yes 4  15.4%
Other comorbidities
No  38  65.5%
Yes 20  34.5%
Hearing  loss  time  (years)
Mean  6.7
Median  5.0
Minimum  1.0
Maximum  25.0
Standard  deviation  4.9
Hearing  risk  (exposure  to  occupational  noise  and  to
ototoxics)
No 52  89.7%
Yes 6  10.3%
Otoscopy
t
w
s
a
r
i7 1  1.7%
The  entire  group  was  interviewed  in  detail  about  their
medical  history,  and  the  data  were  recorded.  Then,  par-
ticipants  were  asked  to  give  information  about  hearing
loss  duration,  use  (or  not)  of  hearing  aids,  hyperten-
sion,  dyslipidemia,  heart  disease,  thyroid  disease,  and
osteoarthropathy,  and  also  in  men,  benign  prostatic  hyper-
plasia.  The  subjects  were  also  asked  about  possible  exposure
to  ototoxic  substances  or  noisy  environments,  i.e.,  an
exogenous  auditory  risk.  In  addition,  a  clinical  exam  was
performed,  focused  on  otoscopy.
Patients  were  treated  for  a  period  of  six  months.
They  were  allocated  into  four  groups  and  treated  with
one  of  the  following  regimens:  dry  extract  of  G.  biloba
(120  mg/day),  -lipoic  acid  (60  mg/day)  plus  vitamin  C
(600  mg/day),  papaverine  hydrochloride  (100  mg/day)  plus
vitamin  E  (400  mg/day),  and  placebo  (starch  capsules).
The  substances  were  not  identiﬁed  by  name  in  the  con-
tainers  into  which  they  were  packed,  but  rather  through
symbols  deﬁned  by  a  professional  who  did  not  participate
in  the  research,  as  a  way  of  blinding  investigators  and
patients.  For  distribution  and  randomization  of  participants,
R
T
TNo distinctive  factors  57  98.3%
Bilateral  tympanosclerosis  1  1.7%
he  resources  available  at  http://www.randomization.com
ere  used.
The  statistical  tests  used  in  the  analysis  included  Pear-
on’s  chi-squared  test,  Fisher’s  exact  test  (or  its  extension),
nd  analysis  of  variance  with  parametric  and  non-parametric
epeated  measures.  In  all  conclusions  reached  through  the
nferential  analysis,  the  signiﬁcance  level  ˛  =  5%  was  used.esults
he  general  epidemiological  data  of  the  sample  are  listed  in
able  1.
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Table  3  Distribution  of  Tinnitus  Handicap  Inventory  (THI)  by  degree  of  subjects  with  complaint  of  tinnitus,  for  placebo  (P),
Ginkgo biloba  120  mg/day  (GB),  -lipoic  acid  60  mg/day  plus  vitamin  C  600  mg/day  (AA  +  VC),  and  papaverine  hydrochloride
100 mg/day  plus  vitamin  E  400  mg/day  (PP  +  VE)  groups,  before  and  after  treatment  time  points.
P  GB  AA  +  VC  PP  +  VE
THI  degree  --  before
1  7  53.8%  3  25.0%  3  23.1%  4  26.7%
2 2  15.4% 5  41.7% 5  38.5%  8  53.3%
3 1  7.7% 3  25.0% 1  7.7%  1  6.7%
4 3  23.1%  --  --  4  30.8%  1  6.7%
5 --  --  1  8.3%  --  --  1  6.7%
Total 13  100.0%  12  100.0%  13  100.0%  15  100.0%
THI degree  --  after
1  7  53.8%  3  25.0%  4  30.8%  4  26.7%
2 3  23.1%  5  41.7%  5  38.5%  6  40.0%
3 1  7.7%  1  8.3%  --  --  3  20.0%
4 2  15.4%  2  16.7%  4  30.8%  1  6.7%
5 --  --  1  8.3%  --  --  1  6.7%
Total 13  100.0%  12  100.0%  13  100.0%  15  100.0%
a
w
t
w
t
b
t
(
t
b
(
D
A
t
t
d
a
t
h
ﬂ
pThe  most  signiﬁcant  general  clinical  data  of  the  sample
re  listed  in  Table  2.
Table  3  lists  the  distribution  of  THI  by  degree  for  subjects
ith  complaints  of  tinnitus,  in  the  different  groups  and  in
he  time  points  before  and  after  treatment.
Table  4  lists  the  distribution  of  THI  in  scores  for  subjects
ith  complaints  of  tinnitus,  in  the  different  groups  and  in
he  time  points  before  and  after  treatment.
After  statistical  analysis,  it  was  concluded  that  THI
efore  treatment  was  statistically  equivalent  to  THI  after
reatment,  both  by  degree  (p  =  0.441)  and  by  score
p  = 0.848).  Additionally,  the  inferential  results  revealed
hat  the  four  treatment  groups  were  statistically  equivalent,
oth  in  THI  expressed  by  degree  (p  =  0.663)  and  by  score
p  = 0.715).

p
t
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Table  4  Distribution  of  Tinnitus  Handicap  Inventory  (THI)  by  sc
Ginkgo biloba  120  mg/day  (GB),  -lipoic  acid  60  mg/day  plus  vita
100 mg/day  plus  vitamin  E  400  mg/day  (PP  +  VE)  groups,  before  and
P  
THI  score  --  before
n  13  
Mean 28.2  
Median 14.0  
Minimum--maximum  2--72  
Standard deviation  25.1  
THI score  --  after
n  13  
Mean 24.2  
Median 14.0  
Minimum--maximum  0--64  
Standard deviation  23.1  
Pearson’s chi-squared test (p = 0.848). THI before and THI after treatmiscussion
 number  of  antioxidants  have  been  studied,  showing  posi-
ive  effects  in  several  clinical  conditions.13--15 In  this  study,
he  choice  of  the  selected  substances  was  based  on  the  evi-
ence  and  descriptions  in  the  literature,  both  in  clinical
nd  experimental  research,  and  also  on  their  availability  in
his  community.  Brieﬂy,  G.  biloba  can  be  described  as  an
erbal  medicine  whose  active  pharmacological  groups  are
avonoids  with  antioxidant  and  vasodilator  action,  and  ter-
ene  lactones,  which  act  as  antiplatelet  agents.16 Originally,
-lipoic  acid  was  considered  as  part  of  the  vitamin  B  com-
lex,  but  now  is  no  longer  considered  as  a  vitamin,  because
here  is  evidence  that  this  substance  can  be  synthesized  by
he  human  body.  -Lipoic  acid  has  an  antioxidant  effect  and
ore  of  subjects  with  complaint  of  tinnitus,  for  placebo  (P),
min  C  600  mg/day  (AA  +  VC),  and  papaverine  hydrochloride
 after  treatment  time  points.
GB  AA  +  VC  PP  +  VE
12  13  15
32.8  38.8  28.0
29.0  32.0  24.0
12--80  4--76  2--96
19.9  24.7  23.8
12  13  15
34.8  32.5  30.4
24.0  24.0  24.0
6--80  0--72  2--96
24.7  25.5  25.0
ent, by score.
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also  an  oxidative  reduction  effect  on  other  antioxidants.14
Vitamin  E  is  an  essential  fat-soluble  vitamin  whose  main
function  is  related  to  the  lipid  stability  of  cell  membranes
against  oxygen  free  radicals.  This  vitamin  also  has  a  modu-
lating  effect  on  cell  growth,  in  response  to  oxidative  stress,
hence  its  positive  effect  on  atherosclerosis  and  certain
neoplasms.17 Vitamin  C  or  ascorbic  acid  is  a  water-soluble
vitamin,  critical  for  collagen  and  l-carnitine  biosynthesis,
for  the  conversion  of  dopamine  to  norepinephrine;  it  also
improves  iron  absorption.  Under  physiological  conditions,
this  vitamin  also  acts  as  a  potent  antioxidant.18 Papaver-
ine  hydrochloride  is  a  synthetic  alkaloid  that  exerts  a tissue
protective  effect  correlated  to  antioxidants,  because  this
substance  promotes  non-speciﬁc  smooth  muscle  relaxation,
leading  to  vasodilation.19 Antioxidants  act  synergistically
with  other  agents  or  in  isolation,  functioning  in  different
ways,  protecting  cell  membranes  and  also  eliminating  oxy-
gen  free  radicals.4,6
The  afﬂictions  of  the  auditory  apparatus  are  complex
conditions  that  involve  a  number  of  physical  phenomena,
various  tissues,  and  different  topographies  of  the  auditory
pathway.  Tinnitus  appears  to  be  caused  by  abnormal  neu-
ral  activity  in  cochlea--auditory  cortex  pathway.20 There  is  a
consensus  in  the  literature  that  at  least  some  of  the  changes
found  along  the  auditory  pathway  and  related  to  auditory
symptoms  appear  to  be  related  to  biochemical  changes,
inﬂammation,  and  injuries  induced  by  free  radicals.8
The  main  cause  of  tinnitus  is  damage  to  hearing  sen-
sory  cells  of  the  cochlea,  with  or  without  association  to  an
injury  of  central  auditory  system  structures,  through  several
etiopathogenic  mechanisms.21 Subjects  with  normal  hearing
may  also  have  tinnitus;  however,  patients  with  hearing  loss
may  not  have  tinnitus.  The  sample  of  this  study  was  entirely
composed  of  subjects  with  tinnitus  and  sensorineural  hear-
ing  loss.
With  regard  to  the  sample,  anticoagulant  users  were
excluded  due  to  the  chance  of  bleeding  when  these  drugs
are  combined  with  G.  biloba,  which  have  an  antithrombotic
effect.  Another  group  excluded  was  diabetics,  due  to  the
chance  of  glycemic  imbalance  when  in  combination  with  -
lipoic  acid.14 Given  the  authors’  intention  to  test  several
substances  in  a  very  deﬁned  population  group,  the  groups
had  a  relatively  limited  number  of  subjects,  but  they  were
methodologically  sound  for  this  study  and  its  statistical  eval-
uation.
The  substances  chosen  were  processed  in  a  compounding
pharmacy,  since  the  combinations  used  are  not  commercially
available.  This  was  also  important  in  the  blinding  process,
since  the  substances  were  packaged  in  identical  capsules
and  identical  bottles,  but  were  identiﬁed  by  different  sym-
bols,  so  they  could  not  be  identiﬁed  by  the  subjects  or
researchers.  The  person  responsible  for  handling  the  sub-
stances  was  aware  of  this  condition.  The  doses  of  substances
used  were  based  on  what  the  literature  recommends  as
an  effective  and  clinically  safe  dose.  In  this  study,  there
were  no  adverse  effects  with  these  substances  during  the
study  period  and  at  the  doses  used.  Moreover,  according
to  the  literature  and  pharmacological  research,  there  are
no  reports  on  the  associations  of  substances  proposed  in
this  study,  nor  information  to  indicate  that,  once  associ-
ated,  they  could  show  decreased  interaction  or  summation
of  their  effects.  This  was  corroborated  by  our  results,  since273
o  modiﬁcation  of  the  researched  symptom  occurred  after
reatment.
The  effects  of  antioxidant  therapy  for  tinnitus  were
valuated  through  THI,12 a  validated  and  widely  used  ques-
ionnaire  to  evaluate  the  inﬂuence  of  tinnitus  on  quality
f  life  of  the  subjects  tested.  As  described  earlier,  there
as  no  observable  effect  of  the  antioxidants  on  tinnitus  in
he  sample  groups  for  a  period  of  six  months.  Some  reports
ndicate  that  the  use  of  B-complex  vitamins  could  be  bene-
cial  in  controlling  tinnitus.  However,  no  controlled  clinical
rial  has  proven  this  hypothesis.22 Regarding  G.  biloba  in  the
reatment  of  tinnitus,  a systematic  review  evaluating  stud-
es  on  the  use  of  this  substance  (in  its  EGb  761  presentation)
as  demonstrated  efﬁcacy  when  compared  to  placebo.23
nother  Cochrane  group  review  conducted  in  2013  did  not
emonstrate  efﬁcacy  of  G.  biloba  in  the  treatment  of  tinni-
us,  irrespective  of  the  form  in  which  the  plant  extract  was
btained.24 The  present  study  used  compounded  dry  extract
f  G.  biloba.
These  ﬁndings  also  corroborate  a  recent  international
ecommendation,  against  prescribing  vitamin  and  dietary
upplements  for  the  treatment  of  patients  with  persistent
nd  clinically  relevant  tinnitus.25
onclusion
n  the  time  interval  and  sample  evaluated,  we  observed  no
tatistically  signiﬁcant  beneﬁt  from  the  use  of  antioxidants
or  tinnitus.
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